BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 28394918)

  • 1. A novel technique of serial biopsy in mouse brain tumour models.
    Rogers S; Hii H; Huang J; Ancliffe M; Gottardo NG; Dallas P; Lee S; Endersby R
    PLoS One; 2017; 12(4):e0175169. PubMed ID: 28394918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Pre-Clinical Assessment of the Pan-ERBB Inhibitor Dacomitinib in Pediatric and Adult Brain Tumors.
    Endersby R; Whitehouse J; Hii H; Greenall SA; Johns TG; Gottardo NG
    Neoplasia; 2018 May; 20(5):432-442. PubMed ID: 29574250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease.
    Radaelli E; Ceruti R; Patton V; Russo M; Degrassi A; Croci V; Caprera F; Stortini G; Scanziani E; Pesenti E; Alzani R
    Histol Histopathol; 2009 Jul; 24(7):879-91. PubMed ID: 19475534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma.
    Laramy JK; Kim M; Gupta SK; Parrish KE; Zhang S; Bakken KK; Carlson BL; Mladek AC; Ma DJ; Sarkaria JN; Elmquist WF
    J Pharmacol Exp Ther; 2017 Nov; 363(2):136-147. PubMed ID: 28847917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor effect of NK012, a 7-ethyl-10-hydroxycamptothecin-incorporating polymeric micelle, on U87MG orthotopic glioblastoma in mice compared with irinotecan hydrochloride in combination with bevacizumab.
    Kuroda J; Kuratsu J; Yasunaga M; Koga Y; Kenmotsu H; Sugino T; Matsumura Y
    Clin Cancer Res; 2010 Jan; 16(2):521-9. PubMed ID: 20068081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma.
    Zahonero C; Aguilera P; Ramírez-Castillejo C; Pajares M; Bolós MV; Cantero D; Perez-Nuñez A; Hernández-Laín A; Sánchez-Gómez P; Sepúlveda JM
    Mol Cancer Ther; 2015 Jul; 14(7):1548-58. PubMed ID: 25939761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrin alphavbeta3-targeted radioimmunotherapy of glioblastoma multiforme.
    Veeravagu A; Liu Z; Niu G; Chen K; Jia B; Cai W; Jin C; Hsu AR; Connolly AJ; Tse V; Wang F; Chen X
    Clin Cancer Res; 2008 Nov; 14(22):7330-9. PubMed ID: 19010848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.
    Ma Y; Tang N; Thompson RC; Mobley BC; Clark SW; Sarkaria JN; Wang J
    Clin Cancer Res; 2016 Apr; 22(7):1767-76. PubMed ID: 26561558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
    Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
    Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dactolisib (NVP-BEZ235) toxicity in murine brain tumour models.
    Netland IA; Førde HE; Sleire L; Leiss L; Rahman MA; Skeie BS; Gjerde CH; Enger PØ; Goplen D
    BMC Cancer; 2016 Aug; 16():657. PubMed ID: 27542970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation.
    Eskilsson E; Rosland GV; Talasila KM; Knappskog S; Keunen O; Sottoriva A; Foerster S; Solecki G; Taxt T; Jirik R; Fritah S; Harter PN; Välk K; Al Hossain J; Joseph JV; Jahedi R; Saed HS; Piccirillo SG; Spiteri I; Leiss L; Euskirchen P; Graziani G; Daubon T; Lund-Johansen M; Enger PØ; Winkler F; Ritter CA; Niclou SP; Watts C; Bjerkvig R; Miletic H
    Neuro Oncol; 2016 Dec; 18(12):1644-1655. PubMed ID: 27286795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect.
    Szentirmai O; Baker CH; Lin N; Szucs S; Takahashi M; Kiryu S; Kung AL; Mulligan RC; Carter BS
    Neurosurgery; 2006 Feb; 58(2):365-72; discussion 365-72. PubMed ID: 16462491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect.
    Zhan C; Gu B; Xie C; Li J; Liu Y; Lu W
    J Control Release; 2010 Apr; 143(1):136-42. PubMed ID: 20056123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment.
    Tanaka K; Sasayama T; Irino Y; Takata K; Nagashima H; Satoh N; Kyotani K; Mizowaki T; Imahori T; Ejima Y; Masui K; Gini B; Yang H; Hosoda K; Sasaki R; Mischel PS; Kohmura E
    J Clin Invest; 2015 Apr; 125(4):1591-602. PubMed ID: 25798620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of submicron/nanoscale PLGA implants to deliver paclitaxel with enhanced pharmacokinetics and therapeutic efficacy in intracranial glioblastoma in mice.
    Ranganath SH; Fu Y; Arifin DY; Kee I; Zheng L; Lee HS; Chow PK; Wang CH
    Biomaterials; 2010 Jul; 31(19):5199-207. PubMed ID: 20350766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma.
    Salphati L; Alicke B; Heffron TP; Shahidi-Latham S; Nishimura M; Cao T; Carano RA; Cheong J; Greve J; Koeppen H; Lau S; Lee LB; Nannini-Pepe M; Pang J; Plise EG; Quiason C; Rangell L; Zhang X; Gould SE; Phillips HS; Olivero AG
    Drug Metab Dispos; 2016 Dec; 44(12):1881-1889. PubMed ID: 27638506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiolabeled novel mAb 4G1 for immunoSPECT imaging of EGFRvIII expression in preclinical glioblastoma xenografts.
    Liu X; Dong C; Shi J; Ma T; Jin Z; Jia B; Liu Z; Shen L; Wang F
    Oncotarget; 2017 Jan; 8(4):6364-6375. PubMed ID: 28031526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroPET/CT imaging of an orthotopic model of human glioblastoma multiforme and evaluation of pulsed low-dose irradiation.
    Park SS; Chunta JL; Robertson JM; Martinez AA; Oliver Wong CY; Amin M; Wilson GD; Marples B
    Int J Radiat Oncol Biol Phys; 2011 Jul; 80(3):885-92. PubMed ID: 21489704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.
    Piao Y; Park SY; Henry V; Smith BD; Tiao N; Flynn DL; de Groot JF
    Neuro Oncol; 2016 Sep; 18(9):1230-41. PubMed ID: 26965451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.